Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: From 'mind the gap' to 'where's the gap?'

Kate Childs; Chris Taylor; Douglas Dieterich; Kosh Agarwal

doi:10.1097/QAD.0000000000001042

Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: From 'mind the gap' to 'where's the gap?'

Kate Childs^*, Chris Taylor, Douglas Dieterich, Kosh Agarwal

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

9 Citations (Scopus)

Abstract

In patients living with HIV infection with hepatitis C (HCV) is common. HIV/HCV co-infection results in more rapid liver fibrosis progression than HCV alone and end-stage liver disease is a major cause of morbidity and mortality in co-infected patients. Historically, treatment outcomes with interferon based therapy in this group have been poor but with the advent of directly acting antiviral (DAA) drugs for HCV, rates of cure have improved dramatically. This article reviews recent evidence on the treatment of HCV in co-infected patients including the efficacy of new regimens and information on drug-drug interactions between DAAs and antiretroviral therapy. We also discuss the relationship between the pathogenesis of HIV and HCV infections, the treatment of acute hepatitis C and the current debate regarding the cost-effectiveness and affordability of DAAs.

Original language	English
Pages (from-to)	975-989
Number of pages	15
Journal	Aids
Volume	30
Issue number	7
DOIs	https://doi.org/10.1097/QAD.0000000000001042
Publication status	Published - 24 Apr 2016

Keywords

directly acting antiviral
hepatitis C virus
HIV

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/QAD.0000000000001042

Cite this

@article{9679bd0df625451b9ca8c2b7662eced5,

title = "Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: From 'mind the gap' to 'where's the gap?'",

abstract = "In patients living with HIV infection with hepatitis C (HCV) is common. HIV/HCV co-infection results in more rapid liver fibrosis progression than HCV alone and end-stage liver disease is a major cause of morbidity and mortality in co-infected patients. Historically, treatment outcomes with interferon based therapy in this group have been poor but with the advent of directly acting antiviral (DAA) drugs for HCV, rates of cure have improved dramatically. This article reviews recent evidence on the treatment of HCV in co-infected patients including the efficacy of new regimens and information on drug-drug interactions between DAAs and antiretroviral therapy. We also discuss the relationship between the pathogenesis of HIV and HCV infections, the treatment of acute hepatitis C and the current debate regarding the cost-effectiveness and affordability of DAAs.",

keywords = "directly acting antiviral, hepatitis C virus, HIV",

author = "Kate Childs and Chris Taylor and Douglas Dieterich and Kosh Agarwal",

year = "2016",

month = apr,

day = "24",

doi = "10.1097/QAD.0000000000001042",

language = "English",

volume = "30",

pages = "975--989",

journal = "Aids",

issn = "0269-9370",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients

T2 - From 'mind the gap' to 'where's the gap?'

AU - Childs, Kate

AU - Taylor, Chris

AU - Dieterich, Douglas

AU - Agarwal, Kosh

PY - 2016/4/24

Y1 - 2016/4/24

N2 - In patients living with HIV infection with hepatitis C (HCV) is common. HIV/HCV co-infection results in more rapid liver fibrosis progression than HCV alone and end-stage liver disease is a major cause of morbidity and mortality in co-infected patients. Historically, treatment outcomes with interferon based therapy in this group have been poor but with the advent of directly acting antiviral (DAA) drugs for HCV, rates of cure have improved dramatically. This article reviews recent evidence on the treatment of HCV in co-infected patients including the efficacy of new regimens and information on drug-drug interactions between DAAs and antiretroviral therapy. We also discuss the relationship between the pathogenesis of HIV and HCV infections, the treatment of acute hepatitis C and the current debate regarding the cost-effectiveness and affordability of DAAs.

AB - In patients living with HIV infection with hepatitis C (HCV) is common. HIV/HCV co-infection results in more rapid liver fibrosis progression than HCV alone and end-stage liver disease is a major cause of morbidity and mortality in co-infected patients. Historically, treatment outcomes with interferon based therapy in this group have been poor but with the advent of directly acting antiviral (DAA) drugs for HCV, rates of cure have improved dramatically. This article reviews recent evidence on the treatment of HCV in co-infected patients including the efficacy of new regimens and information on drug-drug interactions between DAAs and antiretroviral therapy. We also discuss the relationship between the pathogenesis of HIV and HCV infections, the treatment of acute hepatitis C and the current debate regarding the cost-effectiveness and affordability of DAAs.

KW - directly acting antiviral

KW - hepatitis C virus

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=84962659275&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001042

DO - 10.1097/QAD.0000000000001042

M3 - Editorial

AN - SCOPUS:84962659275

SN - 0269-9370

VL - 30

SP - 975

EP - 989

JO - Aids

JF - Aids

IS - 7

ER -

Directly acting antivirals for hepatitis C virus arrive in HIV/hepatitis C virus co-infected patients: From 'mind the gap' to 'where's the gap?'

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this